1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies

A series of 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridines differently substituted at positions 1, 5, and 9 have been designed from the pyrano[3,2-c]quinoline derivative 1, a weak inhibitor of acetylcholinesterase (AChE) with predicted ability to bind to the AChE peripheral anionic site (PAS), at the entrance of the catalytic gorge. Fourteen novel benzonaphthyridines have been synthesized through synthetic sequences involving as the key step a multicomponent Povarov reaction between an aldehyde, an aniline and an enamine or an enamide as the activated alkene. The novel compounds have been tested against Electrophorus electricus AChE (EeAChE), human recombinant AChE (hAChE), and human serum butyrylcholinesterase (hBChE), and their brain penetration has been assessed using the PAMPA-BBB assay. Also, the mechanism of AChE inhibition of the most potent compounds has been thoroughly studied by kinetic studies, a propidium displacement assay, and molecular modelling. We have found that a seemingly small structural change such as a double O → NH bioisosteric replacement from the hit 1 to 16a results in a dramatic increase of EeAChE and hAChE inhibitory activities (>217- and >154-fold, respectively), and in a notable increase in hBChE inhibitory activity (> 11-fold), as well. An optimized binding at the PAS besides additional interactions with AChE midgorge residues seem to account for the high hAChE inhibitory potency of 16a (IC50 = 65 nM), which emerges as an interesting anti-Alzheimer lead compound with potent dual AChE and BChE inhibitory activities.

1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies

A series of 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridines differently substituted at positions 1, 5, and 9 have been designed from the pyrano[3,2-c]quinoline derivative 1, a weak inhibitor of acetylcholinesterase (AChE) with predicted ability to bind to the AChE peripheral anionic site (PAS), at the entrance of the catalytic gorge. Fourteen novel benzonaphthyridines have been synthesized through synthetic sequences involving as the key step a multicomponent Povarov reaction between an aldehyde, an aniline and an enamine or an enamide as the activated alkene. The novel compounds have been tested against Electrophorus electricus AChE (EeAChE), human recombinant AChE (hAChE), and human serum butyrylcholinesterase (hBChE), and their brain penetration has been assessed using the PAMPA-BBB assay. Also, the mechanism of AChE inhibition of the most potent compounds has been thoroughly studied by kinetic studies, a propidium displacement assay, and molecular modelling. We have found that a seemingly small structural change such as a double O → NH bioisosteric replacement from the hit 1 to 16a results in a dramatic increase of EeAChE and hAChE inhibitory activities (>217- and >154-fold, respectively), and in a notable increase in hBChE inhibitory activity (> 11-fold), as well. An optimized binding at the PAS besides additional interactions with AChE midgorge residues seem to account for the high hAChE inhibitory potency of 16a (IC50 = 65 nM), which emerges as an interesting anti-Alzheimer lead compound with potent dual AChE and BChE inhibitory activities.

1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies

A series of 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridines differently substituted at positions 1, 5, and 9 have been designed from the pyrano[3,2-c]quinoline derivative 1, a weak inhibitor of acetylcholinesterase (AChE) with predicted ability to bind to the AChE peripheral anionic site (PAS), at the entrance of the catalytic gorge. Fourteen novel benzonaphthyridines have been synthesized through synthetic sequences involving as the key step a multicomponent Povarov reaction between an aldehyde, an aniline and an enamine or an enamide as the activated alkene. The novel compounds have been tested against Electrophorus electricus AChE (EeAChE), human recombinant AChE (hAChE), and human serum butyrylcholinesterase (hBChE), and their brain penetration has been assessed using the PAMPA-BBB assay. Also, the mechanism of AChE inhibition of the most potent compounds has been thoroughly studied by kinetic studies, a propidium displacement assay, and molecular modelling. We have found that a seemingly small structural change such as a double O → NH bioisosteric replacement from the hit 1 to 16a results in a dramatic increase of EeAChE and hAChE inhibitory activities (>217- and >154-fold, respectively), and in a notable increase in hBChE inhibitory activity (> 11-fold), as well. An optimized binding at the PAS besides additional interactions with AChE midgorge residues seem to account for the high hAChE inhibitory potency of 16a (IC50 = 65 nM), which emerges as an interesting anti-Alzheimer lead compound with potent dual AChE and BChE inhibitory activities.

1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies

A series of 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridines differently substituted at positions 1, 5, and 9 have been designed from the pyrano[3,2-c]quinoline derivative 1, a weak inhibitor of acetylcholinesterase (AChE) with predicted ability to bind to the AChE peripheral anionic site (PAS), at the entrance of the catalytic gorge. Fourteen novel benzonaphthyridines have been synthesized through synthetic sequences involving as the key step a multicomponent Povarov reaction between an aldehyde, an aniline and an enamine or an enamide as the activated alkene. The novel compounds have been tested against Electrophorus electricus AChE (EeAChE), human recombinant AChE (hAChE), and human serum butyrylcholinesterase (hBChE), and their brain penetration has been assessed using the PAMPA-BBB assay. Also, the mechanism of AChE inhibition of the most potent compounds has been thoroughly studied by kinetic studies, a propidium displacement assay, and molecular modelling. We have found that a seemingly small structural change such as a double O → NH bioisosteric replacement from the hit 1 to 16a results in a dramatic increase of EeAChE and hAChE inhibitory activities (>217- and >154-fold, respectively), and in a notable increase in hBChE inhibitory activity (> 11-fold), as well. An optimized binding at the PAS besides additional interactions with AChE midgorge residues seem to account for the high hAChE inhibitory potency of 16a (IC50 = 65 nM), which emerges as an interesting anti-Alzheimer lead compound with potent dual AChE and BChE inhibitory activities.

1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies

A series of 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridines differently substituted at positions 1, 5, and 9 have been designed from the pyrano[3,2-c]quinoline derivative 1, a weak inhibitor of acetylcholinesterase (AChE) with predicted ability to bind to the AChE peripheral anionic site (PAS), at the entrance of the catalytic gorge. Fourteen novel benzonaphthyridines have been synthesized through synthetic sequences involving as the key step a multicomponent Povarov reaction between an aldehyde, an aniline and an enamine or an enamide as the activated alkene. The novel compounds have been tested against Electrophorus electricus AChE (EeAChE), human recombinant AChE (hAChE), and human serum butyrylcholinesterase (hBChE), and their brain penetration has been assessed using the PAMPA-BBB assay. Also, the mechanism of AChE inhibition of the most potent compounds has been thoroughly studied by kinetic studies, a propidium displacement assay, and molecular modelling. We have found that a seemingly small structural change such as a double O → NH bioisosteric replacement from the hit 1 to 16a results in a dramatic increase of EeAChE and hAChE inhibitory activities (>217- and >154-fold, respectively), and in a notable increase in hBChE inhibitory activity (> 11-fold), as well. An optimized binding at the PAS besides additional interactions with AChE midgorge residues seem to account for the high hAChE inhibitory potency of 16a (IC50 = 65 nM), which emerges as an interesting anti-Alzheimer lead compound with potent dual AChE and BChE inhibitory activities.

Estudi teòric de nanotubs de nitrur de bor d'interès biomèdic

La integració dels materials biocompatibles en la nanotecnologia ha permès aquesta àrea tenir aplicacions en els camps de la biologia i la medicina, un fet que ha donat lloc a l'aparició de la nanobiotecnologia. La gran majoria d'aquestes aplicacions es basen en un aspecte fonamental: la interacció que es dóna entre els constituents biològics (normalment proteïnes) i els materials biocompatibles. Els nanotubs de carboni presenten una citotoxicitat inherent, mentre que els de nitrur de bor (BNNTs), isòsters amb els de carboni, són inherentment no-citotòxics i mostren una afinitat natural per les proteïnes. En aquesta memòria es presenten els resultats obtinguts de la interacció de BNNTs amb constituents bàsics biomoleculars (molècules que representen grups funcionals i aminoàcids) en absència de solvent mitjançant tècniques de modelatge i càlculs químic-quàntics amb tractament periòdic realitzats amb el codi CRYSTAL09. En primer lloc, s'ha trobat que els mètodes DFT basats en el GGA donen valors de band gap excessivament baixos (2.7 - 4.6 eV) comparat amb el valor experimental (5.5 eV), mentre que el funcional híbrid B3LYP dóna bons valors de band gap, el més acurat essent un BNNT amb índex (9,0), (5.4 eV). S'ha determinat que la interacció de BNNTs amb molècules pot venir guiat per: i) interaccions datives amb el B; ii) enllaç d'H amb el N; iii) interaccions pi-stacking. Les dues primeres forces d'interacció es veuen afavorides en BNNTs de radi petit, els quals interaccionen molt favorablement amb molècules polars, mentre que les terceres es veuen afavorides en BNNTs de radi gran, els quals interaccionen molt favorablement amb sistemes aromàtics o que continguin dobles enllaços. S'ha estudiat la interacció de BNNTs(6,0) amb molècules que contenen grups funcionals presents en residus aminoàcids i s'ha establert una escala d'afinitats relativa, la qual indica que tenen la major interacció aquelles molècules que estableixen interaccions datives B(nanotub)-N(molècula), seguit d’aquelles molècules que poden establir interaccions de tipus pi-stacking, i acabant amb aquelles molècules que estableixen interaccions datives B(nanotub)-O(molècula). Per últim s'ha estudiat la interacció de BNNTs amb diferents aminoàcids (glicina, lisina, àcid glutàmic i fenilalanina) i s'ha establert una escala d'afinitats relativa, la qual està d'acord amb les tendències observades per les molècules que contenen grups funcionals de residus aminoàcids.

Quantum symmetries for exceptional SU(4) modular invariants associated with conformal embeddings

Three exceptional modular invariants of SU(4) exist at levels 4, 6 and 8. They can be obtained from appropriate conformal embeddings and the corresponding graphs have self-fusion. From these embeddings, or from their associated modular invariants, we determine the algebras of quantum symmetries, obtain their generators,and, as a by-product, recover the known graphs E4, E6 and E8 describing exceptional quantum subgroups of type SU(4). We also obtain characteristic numbers (quantum cardinalities, dimensions) for each of them and for their associated quantum groupoïds.

Somatostatin Subtype‑2 Receptor-Targeted Metal-Based Anticancer Complexes

Conjugates of a dicarba analogue of octreotide, a potent somatostatin agonist whose receptors are overexpressed on tumor cells, with [PtCl2(dap)] (dap = 1-(carboxylic acid)-1,2-diaminoethane) (3), [(η6-bip)Os(4-CO2-pico)Cl] (bip = biphenyl, pico = picolinate) (4), [(η6-p-cym)RuCl(dap)]+ (p-cym = p-cymene) (5), and [(η6-p-cym)RuCl(imidazole-CO2H)(PPh3)]+ (6), were synthesized by using a solid-phase approach. Conjugates 35 readily underwent hydrolysis and DNA binding, whereas conjugate 6 was inert to ligand substitution. NMR spectroscopy and molecular dynamics calculations showed that conjugate formation does not perturb the overall peptide structure. Only 6 exhibited antiproliferative activity in human tumor cells (IC50 = 63 ± 2 μM in MCF-7 cells and IC50 = 26 ± 3 μM in DU-145 cells) with active participation of somatostatin receptors in cellular uptake. Similar cytotoxic activity was found in a normal cell line (IC50 = 45 ± 2.6 μM in CHO cells), which can be attributed to a similar level of expression of somatostatin subtype-2 receptor. These studies provide new insights into the effect of receptor-binding peptide conjugation on the activity of metal-based anticancer drugs, and demonstrate the potential of such hybrid compounds to target tumor cells specifically.

1,2-Dimethylindole-3-sulfonyl (MIS) as protecting group for the side chain of arginine

The protection of arginine (Arg) side chains is a crucial issue in peptide chemistry because of the propensity of the basic guanidinium group to produce side reactions. Currently, sulfonyl-type protecting groups, such as 2,2,5,7,8-pentamethylchroman (Pmc) and 2,2,4,6,7-pentamethyldihydrobenzofurane (Pbf), are the most widely used for this purpose. Nevertheless, Arg side chain protection remains problematic as a result of the acid stability of these two compounds. This issue is even more relevant in Arg-rich sequences, acid-sensitive peptides and large-scale syntheses. The 1,2-dimethylindole-3-sulfonyl (MIS) group is more acid-labile than Pmc and Pbf and can therefore be a better option for Arg side chain protection. In addition, MIS is compatible with tryptophan-containing peptides.

Gestión de residuos sanitarios (y 2). Qué facilita y/o dificulta la correcta gestión

Para la protección de la salud pública y evitación de los riesgos laborales derivados de la gestión incorrecta de los residuos sanitarios (RS), es necesario identificar los elementos que facilitan o dificultan las actitudes de prevención frente a la gestión avanzada de los RS. Objetivo: Identificar la actitud de los profesionales de la salud frente a la gestión de los RS. Objetivos específicos: Definir los elementos que dificultan y/o facilitan la eliminación de los RS. Conocer la valoración global que hacen los profesionales de la gestión de los RS. Identificar propuestas para mejorar la gestión de los RS. Material y métodos: La muestra abarca a 108 profesionales sanitarios de 2 centros hospitalarios de Barcelona y 2 centros hospitalarios de L"Hospitalet de Llobregat. Las unidades asistenciales escogidas para el estudio son los servicios de enfermedades infecciosas, medicina interna, urgencias, obstetricia y ginecología, neumología, radiología, oncología, hematología, cuidados intensivos y laboratorio. Se trata de un estudio descriptivo, no probabilístico. Criterios de inclusión: profesionales del turno de mañana, tarde y 12 h con más de un año de experiencia profesional. Criterios de exclusión: profesionales del turno de noche y en período de prácticas. Como instrumento de medida se ha utilizado un cuestionario elaborado y administrado por el equipo investigador. Las variables de estudio son: actitud, valoración global y propuestas. Análisis de los datos: SPSS 12.0. Resultados: Como elementos facilitadores tenemos que el 19,2% considera la percepción de riesgo; el 14,6%, la disponibilidad de recursos; el 10,6%, la formación específica; el 10,6%, la obligación de cumplir la legislación vigente, y el 1,7%, otros. Como factores que dificultan una actitud preventiva en la gestión de RS tenemos: el 16,4%, el desconocimiento de la normativa; el 10,9%, la presión asistencial; el 7,4%, la falta de recursos, y el 4,6%, otros. En cuanto a la valoración global, la mitad de los encuestados están bastante de acuerdo en la gestión realizada en sus unidades asistenciales, y en las propuestas que plantean destaca, con el 54,9%, la necesidad de más formación específica. Conclusiones: La percepción de riesgo, la disponibilidad de recursos y la formación se consideran los factores que facilitan la gestión correcta; y el desconocimiento de la normativa es el elemento que dificulta la misma. La valoración que hacen de la gestión de los RS de los compañeros en sus unidades asistenciales es muy aceptable, y más de la mitad de los profesionales sugieren la formación como la mejor estrategia para la gestión avanzada de los RS.

Gestión de residuos sanitarios (y 2). Qué facilita y/o dificulta la correcta gestión

Para la protección de la salud pública y evitación de los riesgos laborales derivados de la gestión incorrecta de los residuos sanitarios (RS), es necesario identificar los elementos que facilitan o dificultan las actitudes de prevención frente a la gestión avanzada de los RS. Objetivo: Identificar la actitud de los profesionales de la salud frente a la gestión de los RS. Objetivos específicos: Definir los elementos que dificultan y/o facilitan la eliminación de los RS. Conocer la valoración global que hacen los profesionales de la gestión de los RS. Identificar propuestas para mejorar la gestión de los RS. Material y métodos: La muestra abarca a 108 profesionales sanitarios de 2 centros hospitalarios de Barcelona y 2 centros hospitalarios de L"Hospitalet de Llobregat. Las unidades asistenciales escogidas para el estudio son los servicios de enfermedades infecciosas, medicina interna, urgencias, obstetricia y ginecología, neumología, radiología, oncología, hematología, cuidados intensivos y laboratorio. Se trata de un estudio descriptivo, no probabilístico. Criterios de inclusión: profesionales del turno de mañana, tarde y 12 h con más de un año de experiencia profesional. Criterios de exclusión: profesionales del turno de noche y en período de prácticas. Como instrumento de medida se ha utilizado un cuestionario elaborado y administrado por el equipo investigador. Las variables de estudio son: actitud, valoración global y propuestas. Análisis de los datos: SPSS 12.0. Resultados: Como elementos facilitadores tenemos que el 19,2% considera la percepción de riesgo; el 14,6%, la disponibilidad de recursos; el 10,6%, la formación específica; el 10,6%, la obligación de cumplir la legislación vigente, y el 1,7%, otros. Como factores que dificultan una actitud preventiva en la gestión de RS tenemos: el 16,4%, el desconocimiento de la normativa; el 10,9%, la presión asistencial; el 7,4%, la falta de recursos, y el 4,6%, otros. En cuanto a la valoración global, la mitad de los encuestados están bastante de acuerdo en la gestión realizada en sus unidades asistenciales, y en las propuestas que plantean destaca, con el 54,9%, la necesidad de más formación específica. Conclusiones: La percepción de riesgo, la disponibilidad de recursos y la formación se consideran los factores que facilitan la gestión correcta; y el desconocimiento de la normativa es el elemento que dificulta la misma. La valoración que hacen de la gestión de los RS de los compañeros en sus unidades asistenciales es muy aceptable, y más de la mitad de los profesionales sugieren la formación como la mejor estrategia para la gestión avanzada de los RS.

Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting beta-amyloid, tau, and cholinesterase pathologies

Optimization of an essentially inactive 3,4-dihydro-2H-pyrano[3,2-c]quinoline carboxylic ester derivative as acetylcholinesterase (AChE) peripheral anionic site (PAS)-binding motif by double O → NH bioisosteric replacement, combined with molecular hybridization with the AChE catalytic anionic site (CAS) inhibitor 6-chlorotacrine and molecular dynamics-driven optimization of the length of the linker has resulted in the development of the trimethylene-linked 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridine6-chlorotacrine hybrid 5a as a picomolar inhibitor of human AChE (hAChE). The tetra-, penta-, and octamethylene-linked homologues 5bd have been also synthesized for comparison purposes, and found to retain the nanomolar hAChE inhibitory potency of the parent 6-chlorotacrine. Further biological profiling of hybrids 5ad has shown that they are also potent inhibitors of human butyrylcholinesterase and moderately potent Aβ42 and tau anti-aggregating agents, with IC50 values in the submicromolar and low micromolar range, respectively. Also, in vitro studies using an artificial membrane model have predicted a good brain permeability for hybrids 5ad, and hence, their ability to reach their targets in the central nervous system. The multitarget profile of the novel hybrids makes them promising leads for developing anti-Alzheimer drug candidates with more balanced biological activities.

Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting beta-amyloid, tau, and cholinesterase pathologies

Optimization of an essentially inactive 3,4-dihydro-2H-pyrano[3,2-c]quinoline carboxylic ester derivative as acetylcholinesterase (AChE) peripheral anionic site (PAS)-binding motif by double O → NH bioisosteric replacement, combined with molecular hybridization with the AChE catalytic anionic site (CAS) inhibitor 6-chlorotacrine and molecular dynamics-driven optimization of the length of the linker has resulted in the development of the trimethylene-linked 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridine6-chlorotacrine hybrid 5a as a picomolar inhibitor of human AChE (hAChE). The tetra-, penta-, and octamethylene-linked homologues 5bd have been also synthesized for comparison purposes, and found to retain the nanomolar hAChE inhibitory potency of the parent 6-chlorotacrine. Further biological profiling of hybrids 5ad has shown that they are also potent inhibitors of human butyrylcholinesterase and moderately potent Aβ42 and tau anti-aggregating agents, with IC50 values in the submicromolar and low micromolar range, respectively. Also, in vitro studies using an artificial membrane model have predicted a good brain permeability for hybrids 5ad, and hence, their ability to reach their targets in the central nervous system. The multitarget profile of the novel hybrids makes them promising leads for developing anti-Alzheimer drug candidates with more balanced biological activities.

Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting beta-amyloid, tau, and cholinesterase pathologies

Optimization of an essentially inactive 3,4-dihydro-2H-pyrano[3,2-c]quinoline carboxylic ester derivative as acetylcholinesterase (AChE) peripheral anionic site (PAS)-binding motif by double O → NH bioisosteric replacement, combined with molecular hybridization with the AChE catalytic anionic site (CAS) inhibitor 6-chlorotacrine and molecular dynamics-driven optimization of the length of the linker has resulted in the development of the trimethylene-linked 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridine6-chlorotacrine hybrid 5a as a picomolar inhibitor of human AChE (hAChE). The tetra-, penta-, and octamethylene-linked homologues 5bd have been also synthesized for comparison purposes, and found to retain the nanomolar hAChE inhibitory potency of the parent 6-chlorotacrine. Further biological profiling of hybrids 5ad has shown that they are also potent inhibitors of human butyrylcholinesterase and moderately potent Aβ42 and tau anti-aggregating agents, with IC50 values in the submicromolar and low micromolar range, respectively. Also, in vitro studies using an artificial membrane model have predicted a good brain permeability for hybrids 5ad, and hence, their ability to reach their targets in the central nervous system. The multitarget profile of the novel hybrids makes them promising leads for developing anti-Alzheimer drug candidates with more balanced biological activities.

Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting beta-amyloid, tau, and cholinesterase pathologies

Optimization of an essentially inactive 3,4-dihydro-2H-pyrano[3,2-c]quinoline carboxylic ester derivative as acetylcholinesterase (AChE) peripheral anionic site (PAS)-binding motif by double O → NH bioisosteric replacement, combined with molecular hybridization with the AChE catalytic anionic site (CAS) inhibitor 6-chlorotacrine and molecular dynamics-driven optimization of the length of the linker has resulted in the development of the trimethylene-linked 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridine6-chlorotacrine hybrid 5a as a picomolar inhibitor of human AChE (hAChE). The tetra-, penta-, and octamethylene-linked homologues 5bd have been also synthesized for comparison purposes, and found to retain the nanomolar hAChE inhibitory potency of the parent 6-chlorotacrine. Further biological profiling of hybrids 5ad has shown that they are also potent inhibitors of human butyrylcholinesterase and moderately potent Aβ42 and tau anti-aggregating agents, with IC50 values in the submicromolar and low micromolar range, respectively. Also, in vitro studies using an artificial membrane model have predicted a good brain permeability for hybrids 5ad, and hence, their ability to reach their targets in the central nervous system. The multitarget profile of the novel hybrids makes them promising leads for developing anti-Alzheimer drug candidates with more balanced biological activities.